Institute of Medical Technology

The Institute of Medical Technology Magdeburg (IMTM) is a German biotechnology company and research organization specializing in the development of innovative therapies for immune-mediated and neurodegenerative diseases. The company's core expertise lies in the regulation of immune mechanisms through the combined inhibition of specific enzymes, notably alanyl aminopeptidases and dipeptidyl aminopeptidase IV. IMTM operates as a bridge between academic research and industrial application, offering specialized laboratory and clinical research services including large animal studies in cardiology and pneumology. Through strategic partnerships with major drug discovery firms like Evotec and local biotech companies like KeyNeurotek, IMTM advances its proprietary targets from early-stage discovery toward clinical validation.